Mankind Pharma completes Rs 13,768 Cr acquisition of BSV (Biosphere Ventures).

Economy Business

Delhi (New Delhi)-based pharmaceutical company Mankind Pharma Limited has successfully completed the acquisition of a 100% stake in Mumbai (Maharashtra)-based Bharat Serums and Vaccines Limited (BSV) for Rs. 13,768 crores.


      - This acquisition aims to strengthen Mankind Pharma's leadership in the Indian women's health, critical care, and fertility drug markets.

      - The transaction was funded through a combination of internal accruals and external debt, arranged via non-convertible debentures (NCDs) and commercial papers.

     

Main Points:-   (i) The acquisition marks a new chapter in Mankind Pharma's growth journey, as the addition of over 2,500 BSV team members enhances its foundation for accelerated expansion and increased capabilities.

      (ii) BSV offers a specialized portfolio in women's health, with products ranging from fertility drugs to post-pregnancy therapies. It also has a strong presence in the animal bites category, including treatments such as snake venom antiserum and equine rabies immunoglobulin (Ig).


          ____________________________